Show simple item record

dc.contributor.authorTayyar, Yaman
dc.contributor.authorJubair, Luqman
dc.contributor.authorFallaha, Sora
dc.contributor.authorMcMillan, Nigel AJ
dc.date.accessioned2018-04-16T22:04:51Z
dc.date.available2018-04-16T22:04:51Z
dc.date.issued2017
dc.identifier.issn1040-8428
dc.identifier.doi10.1016/j.critrevonc.2017.09.006
dc.identifier.urihttp://hdl.handle.net/10072/373198
dc.description.abstractBackground: Many current anticancer chemotherapeutics suffer from significant side effects, which have led to the exploration of more targeted therapies. This resulted in the exploration of inhibitors of Aurora A kinase as a potential anti-cancer treatment. Alisertib (MLN8237) has proven to be a potent Aurora A kinase inhibitor that had the highest safety profile among its therapeutic family. Phase I/II/III clinical trials with Alisertib have been carried out and reported promising efficacy, yet serious side effects. This article attempts to assess the clinical effect of Alisertib administration in various cancer phenotypes while describing the reported side effects. Methods: Alisertib clinical data were systematically retrieved from Medline, CINAHL, PubMed, and Cochrane Central Register of Controlled Trials and analyzed for quality, relevance, and originality in three stages prior to inclusion. Results: Overall, seven studies met inclusion criteria and enrolled a total of 630 patients. The reported “potential” clinical effect of Alisertib in various tumours is promising as it improved time to disease progression, progression-free survival, and the duration of disease stability. The achieved improvement therefore rationalizes its further investigation as a novel anticancer therapy. However, the administration of the drug was associated with serious haematological disturbances in a relatively high percentage of patients. Conclusion: The evidence of the anti-tumour effect of Alisertib administration is compelling in various types of malignancies. The reported side effects were serious but manageable in many cases. Topical or more targeted routes of administration are suggested when possible to overcome off-target events with systematic administration of the drug.
dc.description.peerreviewedYes
dc.languageEnglish
dc.publisherElsevier
dc.relation.ispartofpagefrom59
dc.relation.ispartofpageto65
dc.relation.ispartofjournalCritical Reviews in Oncology/Hematology
dc.relation.ispartofvolume119
dc.subject.fieldofresearchChemotherapy
dc.subject.fieldofresearchCardiorespiratory Medicine and Haematology
dc.subject.fieldofresearchcode111205
dc.subject.fieldofresearchcode1102
dc.titleCritical risk-benefit assessment of the novel anti-cancer aurora a kinase inhibitor alisertib (MLN8237): A comprehensive review of the clinical data
dc.typeJournal article
dc.type.descriptionC1 - Articles
dc.type.codeC - Journal Articles
dcterms.licensehttp://creativecommons.org/licenses/by-nc-nd/4.0/
dc.description.versionPost-print
gro.facultyGriffith Health, School of Medical Science
gro.rights.copyright© 2017 Elsevier. Licensed under the Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International Licence which permits unrestricted, non-commercial use, distribution and reproduction in any medium, providing that the work is properly cited.
gro.hasfulltextFull Text
gro.griffith.authorMcMillan, Nigel
gro.griffith.authorFallaha, Sora
gro.griffith.authorJubair, Luqman K.
gro.griffith.authorTayyar, Yaman A.


Files in this item

This item appears in the following Collection(s)

  • Journal articles
    Contains articles published by Griffith authors in scholarly journals.

Show simple item record